Skip to main content
SpringerLink
Log in

Fault-il mettre en examen les antiplaquettaires et rechercher une résistance à l’aspirine?

Should antiplatelet agents be monitored and should aspirin resistance be determined?

  • Dossier
  • Published:
BioTribune Magazine

Résumé

Le concept de résistance à l’aspirine responsable de récidive thrombotique est de plus en plus fréquemment rapporté dans la littérature. Toutefois, les mécanismes précis et les conséquences cliniques sont encore mal connus. Dans cette revue, nous envisagerons les conditions de cette résistance biologique et les modalités d’exploration qui sont proposées. L’utilité d’une mise en examen du traitement par l’aspirine, véritable standard antiplaquettaire, reste encore débattue.

Abstract

Aspirin resistance leading to thrombotic recurrence has been extensively reported in the literature. However, its precise mechanisms and clinical outcomes are largely unknown. In this review, we report the conditions governing this resistance and the various tests proposed to explore it. The usefulness of monitoring aspirin therapy remains a debate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

/+/ Références

  1. Eikelhboom JW, Hankey GJ (2003). Aspirin resistance: a new independent predictor of vascular events? J Am Coll Cardiol 41: 966–8

    Article  Google Scholar 

  2. Vane JR, Botting RM (2003). The mechanism of action of aspirin. Thromb Res 110: 255–8

    Article  PubMed  CAS  Google Scholar 

  3. Chandrasekharan NV, Dai H, Roos KL, et al. (2003). Cox-3, a Cox-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning structure and expression. Proc Natl Acad Sci 99: 13926–31

    Article  Google Scholar 

  4. Elalamy I, Samama MM (2000). Aspirin and hemostasis. Rev Med Interne 21 Suppl 1: 27s-34s

    PubMed  Google Scholar 

  5. Valles J, Santos MT, Aznar J, et al. (1998). Erythrocytes promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality. Circulation 97: 350–5

    PubMed  CAS  Google Scholar 

  6. Cotter G, Shemesh E, Zehavi M, et al. (2004). Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 147: 293–300

    Article  PubMed  CAS  Google Scholar 

  7. Schwartz KA, Schwartz DE, Ghosheh K, et al. (2005). Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95: 973–5

    Article  PubMed  CAS  Google Scholar 

  8. Gum PA, Kottke-Marchant K, Poggio ED, et al. (2001). Profil and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–5

    Article  PubMed  CAS  Google Scholar 

  9. Helgason CM, Bolin KM, Hoff JA, et al. (1994). Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25: 2331–6

    PubMed  CAS  Google Scholar 

  10. Gum PA, Kottke-Marchant K, Welsh PA, et al. (2003). A prospective, blind determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41: 961–5

    Article  PubMed  CAS  Google Scholar 

  11. Frelinger AL, Furman MI, Linden MD, et al. (2006). Residual arachidonic-acid-induced platelet activation via an adenosine diphosphate-dependent but cyclo-oxygenase-1 and cyclo-oxygenase-2-independent pathway: a 700-patient study of aspirin-resistance. Circulation 113: 2888–96

    Article  PubMed  CAS  Google Scholar 

  12. Cattaneo M (2004). Aspirin and clopidogrel. Efficacy, safety and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980–7

    Article  PubMed  CAS  Google Scholar 

  13. Cerletti C, Carriero MR, de Gaetano G (1986). Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin. N Engl J Med 314: 316–8

    PubMed  CAS  Google Scholar 

  14. Eikelboom JW, Hirsh J, Weitz JL, et al. (2002). Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–5

    Article  PubMed  CAS  Google Scholar 

  15. Rocca B, Secchiero P, Ciabattoni G et al. (2002). Cyclooxygenase 2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci 99: 7634–9

    Article  PubMed  CAS  Google Scholar 

  16. Cipollone F, Ciabattoni G, Patrignani P, et al. (2000). Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102: 1007–13

    PubMed  CAS  Google Scholar 

  17. Patrono C (2003). Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1: 1710–3

    Article  PubMed  CAS  Google Scholar 

  18. Cornelissen J, Kirtland S, Lim E, et al. (2006). Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function. Thromb Haemost 95: 476–82

    PubMed  CAS  Google Scholar 

  19. Catella-Lawson F, Reilly MP, Kapor SC, et al. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–17

    Article  PubMed  CAS  Google Scholar 

  20. Macdonald TM, Wei L (2003). Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573–4

    Article  PubMed  CAS  Google Scholar 

  21. Santoso S (2001). Platelet polymorphism in thrombotic disorders. Tranfus Clin Biol 8: 261–6

    Article  CAS  Google Scholar 

  22. Cambria-Kiely JA, Ghandi PJ (2002). Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 14: 51–8

    Article  PubMed  CAS  Google Scholar 

  23. Macchi L, Christiaens L, Brabant S, et al. (2003). Resistance in vitro to low dose aspirin is associated with platelet PIA1 (GPIIIa) polymorphism but not with C807T (GPIa/IIa) and C-5T kozak (GPIa). J Am Coll Cardiol 42 (6): 1115–9

    Article  PubMed  CAS  Google Scholar 

  24. Halushka MK, Walker LP, Halushka PV (2003). Genetic variation in cyclooxygenase: effects on response to aspirin. Clin Pharmacol Therap 73: 122–30

    Article  CAS  Google Scholar 

  25. Maree AO, Curtin RJ, Chubb A, et al. (2005). Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3: 2340–5

    Article  PubMed  CAS  Google Scholar 

  26. Buchanan MR, Brister SJ (1995). Individual variation in the effects of ASA on platelet function: implications of the use of ASA clinically. Can J Cardiol 11: 221–7

    PubMed  CAS  Google Scholar 

  27. Mammen EF, Comp PC, Gosselin R, et al. (1998). PFA-100: a new method for assessment of platelet dysfunction. Semin Thromb Haemost 24: 195–202

    Article  CAS  Google Scholar 

  28. Elalamy I (2007). PFA-100: un analyseur global de la qualité fonctionnelle de l’hémostase primaire. RFL 393: 1–11

    Google Scholar 

  29. Chakroun T, Robert F, Lecrubier C, et al. (2004). In vitro resistance to aspirin detected by PFA-100: a pivotal role of Willebrand factor. Br J Hematol 124(1): 80–5

    Article  CAS  Google Scholar 

  30. Harrison P, Segal H, Blasbery K, et al. (2005). Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point of care platelet function tests with optical aggregometry. Stroke 36: 1001–5

    Article  PubMed  CAS  Google Scholar 

  31. Michelson AD, Cattaneo M, Eikelboom JW, et al. (2005). Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost 3: 1309–11

    Article  PubMed  CAS  Google Scholar 

  32. Ohmori T, Yatomi Y, Nonaka T, et al. (2006). Aspirin resistance detected with aggregometry cannot been explained by cyclooxygenase activity: involvement by other signalling pathways in cardiovascular events of aspirin-treated patients J Thromb Haemost 4: 1271–8

    Article  PubMed  CAS  Google Scholar 

  33. Cattaneo M (2007). Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 5(Suppl 1): 230–7

    Article  PubMed  CAS  Google Scholar 

  34. Swallow RA, Agarwala RA, Dawkins KD, et al. (2006). Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 17: 385–92

    Article  PubMed  CAS  Google Scholar 

  35. Elalamy I, Gerotziafas GT, Dumaine C, et al. (2002). Marqueurs de l’hémostase à la phase aiguë de la thrombose coronaire. Arch mal Cœur Vaisseaux 95 (7): 21–9

    Google Scholar 

  36. Goodman T, Sharma P, Ferro A (2007). The gentics of aspirin resistance. Int J Clin Pract 61: 826–34

    Article  PubMed  CAS  Google Scholar 

  37. Campbell CL, Steinhubl SR (2005). Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost 3: 665–9

    Article  PubMed  CAS  Google Scholar 

  38. Fontana P, Nolli S, Reber G, et al. (2006). biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 4: 813–9

    Article  PubMed  CAS  Google Scholar 

  39. Schakroun T, Addad F, Abderazek F, et al. (2007). Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res (sous presse)

  40. Lordkipanidzé M, Pharand C, Schampaert E, et al. (2007). A comparison of six major function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 28: 1702–8

    Article  PubMed  Google Scholar 

  41. Snoep JD, Hovens MM, Eikenboom JC, et al. (2007). Association of laboratory defined aspirin resistance with a higher risk of recurrent cardiovascular events. A systematic review and meta-analysis. Arch Intern Med 167: 1593–9

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie biologique, hôpital Tenon, 4, rue de la Chine, 75020, Paris, France

    I. Elalamy

Authors
  1. I. Elalamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Elalamy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elalamy, I. Fault-il mettre en examen les antiplaquettaires et rechercher une résistance à l’aspirine?. Bio trib. mag. 24, 29–36 (2007). https://doi.org/10.1007/BF03010325

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03010325

Mots clés

Keywords

Search

Navigation